2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework

guest :: login DZNEPUB
		Search		Submit		Personalize Your alerts Your baskets Your searches		Help

Home > Publications Database > 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework > Access to Fulltext

Information
Files

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework - DZNE-2021-00635

Main document file(s):

Similar records

DZNEPUB :: :: :: ::
Powered by v1.1.7 |
Maintained by

Impressum | Data Privacy Policy